Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity

Does the degree of weight regain following tirzepatide withdrawal affect long-term cardiometabolic benefits in individuals with obesity or overweight?In this post hoc analysis of the SURMOUNT-4 randomized clinical trial including 308 participants, participants experienced weight reduction and improvement in cardiometabolic parameters after a 36-week tirzepatide treatment. One year after tirzepatide withdrawal, a higher degree of weight regain was associated with a greater reversal of initial improvements in waist circumference, blood pressure, non–high-density lipoprotein cholesterol, glycemic parameters, and insulin resistance.In this post hoc analysis, on tirzepatide withdrawal, greater reversal of initial cardiometabolic benefits was observed in participants who regained 25% or more of their initial weight reduction vs those who did not.

Corresponding Author: Clare J. Lee, MD, MHS, Eli Lilly and Company, Cardiometabolic Health, Global Medical Affairs, Lilly Corporate Center, Indianapolis, IN 46285 (clare.lee@lilly.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.